Luc Van Rompaey
Luc Van Rompaey is a senior R&D professional with over 18 years Life Sciences experience. He currently serves as VP of Translational Medicine at argenx, leading biomarker studies and translational aspects of argenx clinical programs. Prior to joining Galapagos he performed postdoctoral research in tumor biology in St. Jude Children’s Research Hospital (US) and Leuven University (Belgium).
Before joining argenx, Luc played a pivotal role in the development of Galapagos NV which he joined soon after its inception. He made important contributions to the successful implementation of the functional genomics platform, discovering novel osteoporosis targets that were outlicensed to Procter&Gamble, Wyeth and Eli Lilly. He was instrumental in transitioning Galapagos’ operations from target to drug discovery research. He started the JAK inhibitor research program, led the discovery and contributed to the Development of the JAK1 inhibitor GLPG0634, currently undergoing Phase II trials in rheumatoid arthritis and Crohn’s disease. He served on alliance management teams for drug discovery collaborations with GSK, Eli Lilly and Servier in the fields of osteoarthritis, immunity & inflammation, osteoporosis and oncology.